Clinical Trial Update: Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study evaluating dasatinib and quercetin in combination with CAR-T therapy for relapsed or refractory multiple myeloma; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CAR-T cell therapy
• Quercetin (quercetin)
• Sprycel (dasatinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING